Ig Vena (Human Normal Immunoglobulin)

Human Normal Immunoglobulin supplies exogenous IgG antibodies that circulate in the bloodstream. These antibodies bind to pathogens and toxins, enhance opsonization, neutralize viruses, and modulate immune pathways, thereby compensating for the patient’s deficient endogenous immunoglobulin production.

The dose of Ig Vena is individualized. A qualified prescriber determines the amount, infusion rate, and frequency based on the patient’s weight, severity of immunodeficiency, and clinical response. No fixed regimen is provided in public information.

The pregnancy safety category for Ig Vena is listed as unknown. Use during pregnancy or lactation should only occur when the potential benefit justifies any potential risk, and it must be decided by the treating physician after evaluating the clinical situation.

To order Ig Vena, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and any necessary import documentation.

Ig Vena is comparable to other IVIG products in that it delivers purified human IgG for immunodeficiency replacement. Differences may lie in manufacturing origin, concentration, stabilizers, and regulatory approvals. Clinicians typically select a product based on availability, cost, patient tolerance, and specific formulation characteristics.

Ig Vena must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must never be frozen or shaken. Maintaining the cold chain during transport and handling is essential to preserve product stability.

Ig Vena is administered intravenously as a solution for injection. The infusion is given by a healthcare professional, usually through a peripheral or central line, with the rate adjusted according to patient tolerance and clinical guidelines.

Serious risks include anaphylactic reactions, hemolytic anemia, thromboembolic events, acute renal dysfunction, aseptic meningitis, and severe hypotension. Patients should be closely monitored during and after infusion, and any signs of these reactions require immediate medical attention.

Ig Vena should be avoided in patients with known severe IgA deficiency who have anti‑IgA antibodies, a history of severe allergic reactions to immunoglobulin products, or uncontrolled hyperviscosity. Contraindications are determined by the prescribing clinician based on individual medical history.